Maternal Autoantibody Profiles Are Biomarkers for Autism

By LabMedica International staff writers
Posted on 28 Jun 2022

Image: The Bio-Rad iMark Microplate Absorbance Reader (Photo courtesy of Electronics Depot USA)

Autism is a neurodevelopment condition affecting 1 in 44 children in the U.S. It has a wide range of characteristics with different intensities and causes. One type of autism is maternal autoantibody–related autism spectrum disorder (MAR ASD).

MAR ASD is marked by the presence of specific maternal immune proteins known as autoantibodies that react to certain proteins found in the fetal brain. The maternal autoantibodies (IgG) cross the placenta and access the developing brain. Once there, they may cause changes in the way the brain develops in the offspring, leading to behaviors linked to autism.

Clinical Immunologists at the University of California, Davis (Davis, CA, USA) collected maternal blood mid pregnancy (15–20 weeks of gestation) in citrate dextrose. They used prenatal plasma from mothers of autistic children with or without co-occurring intellectual disability (ASD = 540), intellectual disability without autism (ID = 184) and general population controls (GP = 420).

Plasma was separated, labeled, and stored at −80 °C. Prior to use, samples were thawed at room temperature (RT), vortexed, and centrifuged at 13,000 RPM for 10 minutes. Maternal antibody cross-reactivity against the eight antigens was determined by Enzyme-Linked Immunosorbent Assay (ELISA) using custom-made and commercially available proteins (CRMP1, CRMP2, GDA, NSE, LDHA, LDHB, STIP1, and YBOX). The absorbance was measured at 490-450 nm using an iMark Microplate Absorbance Reader (Bio-Rad Laboratories, Hercules, CA, USA).

The scientists reported that they found reactivity to at least one of the nine MAR ASD patterns in 10% of the autistic group. This is compared with 4% of the intellectual disability group for some patterns, and 1% of the general population group. Four patterns were present only in mothers whose children were later diagnosed with autism, making those particular autoantibody patterns highly predictive.

The study also found that a mother with reactivity to any one of the nine MAR ASD patterns has around eight times the chance of having an autistic child. Several MAR ASD patterns were strongly associated with autism with intellectual disability. Others were linked to autism without intellectual disability. The protein pattern most strongly linked to autism was (CRMP1+CRMP2). It increased the likelihood of an autism diagnosis by 16 times and was not found in the non-autism groups.

Judy Van de Water, PhD, a professor of immunology and neurodevelopment and senior author of the study, said, “Previously, we identified nine patterns linked to MAR ASD. In this study, we wanted to check the accuracy of these patterns in predicting MAR ASD. To do that, we tested plasma from pregnant mothers, collected by the Early Markers for Autism (EMA) study. We hope our work can help develop better-tailored services based on the type of autism and the child's strengths and specific challenges.”

The authors concluded that one of the greatest strengths of their current study was that the samples were collected during mid-pregnancy, demonstrating the predicative value of maternal IgG reactivity against MAR ASD + patterns and child outcomes. The study was published on May 26, 2022 in the journal Molecular Psychiatry.

Related Links:
University of California, Davis
Bio-Rad Laboratories